A citation-based method for searching scientific literature


List of co-cited articles
703 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


50 years of hurdles and hope in anxiolytic drug discovery.
Guy Griebel, Andrew Holmes. Nat Rev Drug Discov 2013
255
14

Anxiety disorders.
Michelle G Craske, Murray B Stein, Thalia C Eley, Mohammed R Milad, Andrew Holmes, Ronald M Rapee, Hans-Ulrich Wittchen. Nat Rev Dis Primers 2017
222
12

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.
N Singewald, C Schmuckermair, N Whittle, A Holmes, K J Ressler. Pharmacol Ther 2015
239
10

Fear extinction as a model for translational neuroscience: ten years of progress.
Mohammed R Milad, Gregory J Quirk. Annu Rev Psychol 2012
887
10

Neuronal circuits for fear and anxiety.
Philip Tovote, Jonathan Paul Fadok, Andreas Lüthi. Nat Rev Neurosci 2015
830
9

D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
David Mataix-Cols, Lorena Fernández de la Cruz, Benedetta Monzani, David Rosenfield, Erik Andersson, Ana Pérez-Vigil, Paolo Frumento, Rianne A de Kleine, JoAnn Difede, Boadie W Dunlop,[...]. JAMA Psychiatry 2017
137
9

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Kerry J Ressler, Barbara O Rothbaum, Libby Tannenbaum, Page Anderson, Ken Graap, Elana Zimand, Larry Hodges, Michael Davis. Arch Gen Psychiatry 2004
701
9


Molecular mechanisms of fear learning and memory.
Joshua P Johansen, Christopher K Cain, Linnaea E Ostroff, Joseph E LeDoux. Cell 2011
636
7

Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder.
Mohammed R Milad, Roger K Pitman, Cameron B Ellis, Andrea L Gold, Lisa M Shin, Natasha B Lasko, Mohamed A Zeidan, Kathryn Handwerger, Scott P Orr, Scott L Rauch. Biol Psychiatry 2009
868
7


Cannabidiol as a Potential Treatment for Anxiety Disorders.
Esther M Blessing, Maria M Steenkamp, Jorge Manzanares, Charles R Marmar. Neurotherapeutics 2015
252
7

Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
Ronald C Kessler, Patricia Berglund, Olga Demler, Robert Jin, Kathleen R Merikangas, Ellen E Walters. Arch Gen Psychiatry 2005
7

Brain circuit dysfunction in post-traumatic stress disorder: from mouse to man.
Robert J Fenster, Lauren A M Lebois, Kerry J Ressler, Junghyup Suh. Nat Rev Neurosci 2018
166
7

Viewpoints: Approaches to defining and investigating fear.
Dean Mobbs, Ralph Adolphs, Michael S Fanselow, Lisa Feldman Barrett, Joseph E LeDoux, Kerry Ressler, Kay M Tye. Nat Neurosci 2019
53
9

Don't stress about CRF: assessing the translational failures of CRF1antagonists.
Samantha R Spierling, Eric P Zorrilla. Psychopharmacology (Berl) 2017
90
7

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.
Ronald C Kessler, Wai Tat Chiu, Olga Demler, Kathleen R Merikangas, Ellen E Walters. Arch Gen Psychiatry 2005
7

Efficacy of treatments for anxiety disorders: a meta-analysis.
Borwin Bandelow, Markus Reitt, Christian Röver, Sophie Michaelis, Yvonne Görlich, Dirk Wedekind. Int Clin Psychopharmacol 2015
211
7

A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study.
Royce J Lee, Emil F Coccaro, Henk Cremers, Rosemary McCarron, Shi-Fang Lu, Michael J Brownstein, Neal G Simon. Front Syst Neurosci 2013
30
16


Neural signatures of human fear conditioning: an updated and extended meta-analysis of fMRI studies.
M A Fullana, B J Harrison, C Soriano-Mas, B Vervliet, N Cardoner, A Àvila-Parcet, J Radua. Mol Psychiatry 2016
305
6

A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.
Barbara Olasov Rothbaum, Matthew Price, Tanja Jovanovic, Seth D Norrholm, Maryrose Gerardi, Boadie Dunlop, Michael Davis, Bekh Bradley, Erica J Duncan, Albert Rizzo,[...]. Am J Psychiatry 2014
216
6

Genetic dissection of an amygdala microcircuit that gates conditioned fear.
Wulf Haubensak, Prabhat S Kunwar, Haijiang Cai, Stephane Ciocchi, Nicholas R Wall, Ravikumar Ponnusamy, Jonathan Biag, Hong-Wei Dong, Karl Deisseroth, Edward M Callaway,[...]. Nature 2010
550
6

Beyond extinction: erasing human fear responses and preventing the return of fear.
Merel Kindt, Marieke Soeter, Bram Vervliet. Nat Neurosci 2009
518
6

An Integrated Neuroscience Perspective on Formulation and Treatment Planning for Posttraumatic Stress Disorder: An Educational Review.
David A Ross, Melissa R Arbuckle, Michael J Travis, Jennifer B Dwyer, Gerrit I van Schalkwyk, Kerry J Ressler. JAMA Psychiatry 2017
80
6

From circuits to behaviour in the amygdala.
Patricia H Janak, Kay M Tye. Nature 2015
951
6

Brain activation during fear extinction predicts exposure success.
Tali Manber Ball, Sarah E Knapp, Martin P Paulus, Murray B Stein. Depress Anxiety 2017
56
7

Mechanisms of fear extinction.
K M Myers, M Davis. Mol Psychiatry 2007
832
6

Dopamine and extinction: a convergence of theory with fear and reward circuitry.
Antony D Abraham, Kim A Neve, K Matthew Lattal. Neurobiol Learn Mem 2014
138
6

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
Stefan G Hofmann, Alicia E Meuret, Jasper A J Smits, Naomi M Simon, Mark H Pollack, Katherine Eisenmenger, Michael Shiekh, Michael W Otto. Arch Gen Psychiatry 2006
359
6

Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.
Boadie W Dunlop, Elisabeth B Binder, Dan Iosifescu, Sanjay J Mathew, Thomas C Neylan, Julius C Pape, Tania Carrillo-Roa, Charles Green, Becky Kinkead, Dimitri Grigoriadis,[...]. Biol Psychiatry 2017
55
7


A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder.
Adam J Guastella, Rick Richardson, Peter F Lovibond, Ronald M Rapee, Jonathan E Gaston, Philip Mitchell, Mark R Dadds. Biol Psychiatry 2008
216
6

Rodent models of impaired fear extinction.
Nicolas Singewald, Andrew Holmes. Psychopharmacology (Berl) 2019
55
7


Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
Vladimir Coric, Howard H Feldman, Dan A Oren, Anantha Shekhar, Joseph Pultz, Randy C Dockens, Xiaoling Wu, Kimberly A Gentile, Shu-Pang Huang, Eileen Emison,[...]. Depress Anxiety 2010
119
6

Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.
Lucas Elms, Scott Shannon, Shannon Hughes, Nicole Lewis. J Altern Complement Med 2019
60
6

Animal models of PTSD: a challenge to be met.
Gal Richter-Levin, Oliver Stork, Mathias V Schmidt. Mol Psychiatry 2019
69
6

Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis.
Mathew Hoskins, Jennifer Pearce, Andrew Bethell, Liliya Dankova, Corrado Barbui, Wietse A Tol, Mark van Ommeren, Joop de Jong, Soraya Seedat, Hanhui Chen,[...]. Br J Psychiatry 2015
184
6

PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR POSTTRAUMATIC STRESS DISORDER: SYSTEMIC REVIEW AND META-ANALYSES TO DETERMINE FIRST-LINE TREATMENTS.
Daniel J Lee, Carla W Schnitzlein, Jonathan P Wolf, Meena Vythilingam, Ann M Rasmusson, Charles W Hoge. Depress Anxiety 2016
168
6

Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.
William Berger, Mauro V Mendlowicz, Carla Marques-Portella, Gustavo Kinrys, Leonardo F Fontenelle, Charles R Marmar, Ivan Figueira. Prog Neuropsychopharmacol Biol Psychiatry 2009
182
6

Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Paul Glue, Natalie J Medlicott, Sarah Harland, Shona Neehoff, Bridie Anderson-Fahey, Martin Le Nedelec, Andrew Gray, Neil McNaughton. J Psychopharmacol 2017
55
7

Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
151
6


The size and burden of mental disorders and other disorders of the brain in Europe 2010.
H U Wittchen, F Jacobi, J Rehm, A Gustavsson, M Svensson, B Jönsson, J Olesen, C Allgulander, J Alonso, C Faravelli,[...]. Eur Neuropsychopharmacol 2011
6

Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.
Ronald C Kessler, Maria Petukhova, Nancy A Sampson, Alan M Zaslavsky, Hans-Ullrich Wittchen. Int J Methods Psychiatr Res 2012
6

Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.
Paul Glue, Shona M Neehoff, Natalie J Medlicott, Andrew Gray, Guy Kibby, Neil McNaughton. J Psychopharmacol 2018
35
11

Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: A randomized placebo-controlled trial.
Andrea Reinecke, Alecia Nickless, Michael Browning, Catherine J Harmer. Behav Res Ther 2020
8
50

Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.
Karine M Fabio, Christophe D Guillon, Shi-Fang Lu, Ned D Heindel, Michael J Brownstein, Carl J Lacey, Carrie Garippa, Neal G Simon. J Pharm Sci 2013
24
16

Treatment-resistant anxiety disorders.
A Bystritsky. Mol Psychiatry 2006
134
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.